We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Elevance Health (ELV) Bolsters CarelonRx With Paragon Buyout
Read MoreHide Full Article
Elevance Health, Inc. (ELV - Free Report) recently announced that it has completed the acquisition of Paragon Healthcare, Inc., the agreement for which was made public in the first week of this year. The strategic move is aimed at boosting its capabilities in multi-site infusion services and specialty pharmacy.
Earlier, Reuters reported that the acquisition would cost ELV more than $1 billion, according to an Axios report. The acquisition is expected to help the company offer affordable and convenient healthcare solutions to its members. The move is likely to enable ELV to offer patients with chronic and complex illnesses better access to specialty medications.
By integrating Paragon Healthcare into its CarelonRx pharmacy services unit, ELV is likely to lower costs of care and provide greater choices on patients’ infused medications. This will enhance its Carelon segment, which includes CarelonRx and Carelon Services. In the last reported quarter, Carelon’s operating revenues improved 14.1% year over year to $12.4 billion, thanks to the expansion of CarelonRx pharmacy product revenues. The company expects the CarelonRx operating margin to witness 40-60 bps growth in 2024.
However, ELV stated earlier that the acquisition is not expected to have a material impact on its 2024 adjusted profits. The infusion services from the acquiree are expected to complement ELV’s suite of pharmacy services. More such deals are expected in the future as the company plans to scale its Carelon business.
Paragon Healthcare’s extensive network of ambulatory infusion centers and home infusion pharmacies across eight states brings a wealth of experience in providing life-saving and life-giving therapies to more than 35,000 patients. ELV intends to further expand Paragon Healthcare’s geographical footprint and therapeutic coverage to ensure that patients have timely access to essential medications. This will increase its pharmacy members served and boost CarelonRx’s pharmacy product revenues.
Price Performance
Elevance Health’s shares have gained 10.5% in the past year compared with the 7.7% rise of the industry.
The Zacks Consensus Estimate for Universal Health Services’ 2024 bottom line suggests 19.9% year-over-year growth. UHS has witnessed three upward estimate revisions over the past 30 days against one movement in the opposite direction. It beat earnings estimates in all the last four quarters, with an average surprise of 5.9%.
The Zacks Consensus Estimate for Cigna’s full-year 2024 earnings indicates a 13% year-over-year increase. CI beat earnings estimates in each of the past four quarters, with an average surprise of 2.9%. The consensus mark for revenues suggests 20.4% growth from the year-ago period.
The Zacks Consensus Estimate for Health Catalyst’s 2024 full-year earnings implies a 93.3% increase from the year-ago reported figure. HCAT beat earnings estimates in each of the last four quarters, with an average surprise of 247.9%. The consensus mark for its current-year revenues is pegged at $308 million, which indicates a 4.1% year-over-year increase.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Elevance Health (ELV) Bolsters CarelonRx With Paragon Buyout
Elevance Health, Inc. (ELV - Free Report) recently announced that it has completed the acquisition of Paragon Healthcare, Inc., the agreement for which was made public in the first week of this year. The strategic move is aimed at boosting its capabilities in multi-site infusion services and specialty pharmacy.
Earlier, Reuters reported that the acquisition would cost ELV more than $1 billion, according to an Axios report. The acquisition is expected to help the company offer affordable and convenient healthcare solutions to its members. The move is likely to enable ELV to offer patients with chronic and complex illnesses better access to specialty medications.
By integrating Paragon Healthcare into its CarelonRx pharmacy services unit, ELV is likely to lower costs of care and provide greater choices on patients’ infused medications. This will enhance its Carelon segment, which includes CarelonRx and Carelon Services. In the last reported quarter, Carelon’s operating revenues improved 14.1% year over year to $12.4 billion, thanks to the expansion of CarelonRx pharmacy product revenues. The company expects the CarelonRx operating margin to witness 40-60 bps growth in 2024.
However, ELV stated earlier that the acquisition is not expected to have a material impact on its 2024 adjusted profits. The infusion services from the acquiree are expected to complement ELV’s suite of pharmacy services. More such deals are expected in the future as the company plans to scale its Carelon business.
Paragon Healthcare’s extensive network of ambulatory infusion centers and home infusion pharmacies across eight states brings a wealth of experience in providing life-saving and life-giving therapies to more than 35,000 patients. ELV intends to further expand Paragon Healthcare’s geographical footprint and therapeutic coverage to ensure that patients have timely access to essential medications. This will increase its pharmacy members served and boost CarelonRx’s pharmacy product revenues.
Price Performance
Elevance Health’s shares have gained 10.5% in the past year compared with the 7.7% rise of the industry.
Image Source: Zacks Investment Research
Zacks Rank & Other Key Picks
Elevance Health currently has a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader Medical space are Universal Health Services, Inc. (UHS - Free Report) , The Cigna Group (CI - Free Report) and Health Catalyst, Inc. (HCAT - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Universal Health Services’ 2024 bottom line suggests 19.9% year-over-year growth. UHS has witnessed three upward estimate revisions over the past 30 days against one movement in the opposite direction. It beat earnings estimates in all the last four quarters, with an average surprise of 5.9%.
The Zacks Consensus Estimate for Cigna’s full-year 2024 earnings indicates a 13% year-over-year increase. CI beat earnings estimates in each of the past four quarters, with an average surprise of 2.9%. The consensus mark for revenues suggests 20.4% growth from the year-ago period.
The Zacks Consensus Estimate for Health Catalyst’s 2024 full-year earnings implies a 93.3% increase from the year-ago reported figure. HCAT beat earnings estimates in each of the last four quarters, with an average surprise of 247.9%. The consensus mark for its current-year revenues is pegged at $308 million, which indicates a 4.1% year-over-year increase.